



Universiteit
Leiden
The Netherlands

CD20 as target for immunotherapy

Engelberts, P.J.

Citation

Engelberts, P. J. (2019, January 10). *CD20 as target for immunotherapy*. Retrieved from <https://hdl.handle.net/1887/68231>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/68231>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/68231> holds various files of this Leiden University dissertation.

Author: Engelberts, P.J.

Title: CD20 as target for immunotherapy

Issue Date: 2019-01-10

CD20 AS TARGET FOR IMMUNOTHERAPY

Cover art

Joost Bakker,
SCICOMVISUALS, Amsterdam,
The Netherlands

Production

Joost Bakker,
SCICOMVISUALS, Amsterdam,
The Netherlands

Design & Dtp

De vliegende kiep,
Amsterdam, The Netherlands

Printed by

Ipskamp Printing, Enschede

ISBN/EAN: 978 94 028 1260 2

Proefschrift Universiteit Leiden,
Faculteit Geneeskunde

© 2018, Petrus Johannes Engelberts,
The Netherlands

Dit proefschrift werd mede
mogelijk gemaakt met financiële
steun van Genmab

CD20 as target for immunotherapy

PROEFSCHRIFT

Ter verkrijging van de graad
van doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus
prof.mr. C.J.J.M. Stolker,
volgens het besluit van het College voor Promoties
te verdedigen op
donderdag 10 Januari 2019
klokke 16:15 uur

door

Petrus Johannes Engelberts

Geboren op 17 September 1975,
te Utrecht

Promotor

Prof. Dr. P.W.H.I. Parren

Co-promotor

Dr. E.C.W. Breij

Promotiecommissie

Prof. Dr. M. de Haas

Prof. Dr. J.J.C. Neefjes

Dr. T. van Hall

Prof. Dr. H. Spits, Academisch Medisch Centrum, Amsterdam

Dr. J.H.W. Leusen, Universitair Medisch Centrum, Utrecht

Voor Lotte en Benjamin

Table of Contents

Chapter 1	General outline and aim of the thesis	9
Chapter 2	The evolution of immunotherapy: lessons learned from targeting CD20	19
Chapter 3	A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab	77
Chapter 4	Type I CD20 antibodies recruit the B-cell receptor for complement-dependent lysis of malignant B cells	99
Chapter 5	Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy	125
Chapter 6	DuoBody [®] -CD3xCD20, an Fc-silenced whole IgG T cell retargeting bispecific antibody, displays unique capacity to induce T-cell mediated kill of malignant B cells, and provides opportunities for subcutaneous dosing	147
Chapter 7	General discussion of the thesis	187
	Summary	217
	Samenvatting in het Nederlands	219
	Dankwoord	222
	Publications	224
	Abbreviations	226
	Curriculum Vitae	232